Avenda Health AI Prostate Cancer Planning Software vs CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Avenda Health AI Prostate Cancer Planning Software
by Avenda Health
VS
CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)
by ConcertAI (an ASCO initiative)

AI Verdict

Avenda Health's Unfold AI is specifically designed for prostate cancer, providing 3D cancer maps to aid in localized treatment planning and decision-making. CancerLinQ SmartLinQ, on the other hand, is a broader precision oncology platform that uses real-world data and AI to identify patients for new therapies and clinical trials across various oncology workflows. While both are oncology AI tools, their primary functions and scope of application differ significantly, making them adjacent rather than direct competitors.

Choose Avenda Health AI Prostate Cancer Planning Software if…

Choose Avenda Health AI Prostate Cancer Planning Software if your primary need is precise, personalized 3D visualization and mapping of prostate cancer for treatment planning. This tool excels at aiding in surgical planning, radiation therapy, focal therapy, and active surveillance by accurately identifying tumor extent and predicting risks like extracapsular extension, improving treatment selection and outcomes.

View Avenda Health AI Prostate Cancer Planning Software →

Choose CancerLinQ SmartLinQ (RxLinQ & TriaLinQ) if…

Choose CancerLinQ SmartLinQ (RxLinQ & TriaLinQ) if your focus is on leveraging real-world data and AI to streamline oncology workflows, particularly for identifying patients for new therapies and clinical trials. This platform is ideal for accelerating patient-to-trial matching, identifying eligibility for newly approved molecularly targeted therapies, and generating real-world evidence to support research and treatment decisions.

View CancerLinQ SmartLinQ (RxLinQ & TriaLinQ) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Avenda Health AI Prostate Cancer Planning Software CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)
Pricing Contact for pricing Contact for pricing
Deployment Cloud-based platform Cloud-based
BAA Available Unknown Yes AI-estimated
FDA Status Yes AI-estimated No AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)

CancerLinQ SmartLinQ emphasizes streamlined clinical workflows and automated quality reporting, which directly translates to improved usability by reducing administrative burdens for staff. Avenda Health AI focuses on generating 3D maps for physicians, which is a specific clinical function rather than overall workflow enhancement.

Clinical Value

Avenda Health AI Prostate Cancer Planning Software

Avenda Health AI provides FDA-cleared, AI-based decision support that creates precise 3D cancer maps, improving the identification of tumor extent (71% improvement, over 98% sensitivity in studies) and aiding in surgical planning and treatment decision-making. CancerLinQ SmartLinQ focuses on identifying patients for therapies and trials using real-world data, which is valuable but not as directly tied to precise, patient-specific diagnostic improvement.

Pricing & Value

Tie

Both tools require contacting the vendor for pricing, indicating a lack of transparency. While Avenda Health AI has a new Category III CPT code for reimbursement, its coverage is not yet universal, and pricing can vary. CancerLinQ SmartLinQ does not provide specific pricing or reimbursement details, making a direct comparison of value difficult.

Enterprise Readiness

CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)

CancerLinQ SmartLinQ is an initiative of ConcertAI, a company with significant scale and a broad network of over 1,900 clinical sites and 45 biomedical innovators. It also highlights enterprise-level dashboards and integration capabilities, including enterprise imaging integration (TeraRecon). Avenda Health AI, while impactful, appears to be a smaller company with a more specialized focus on prostate cancer planning.

Innovation

Avenda Health AI Prostate Cancer Planning Software

Avenda Health AI's core innovation lies in its FDA-cleared AI to create highly accurate 3D cancer estimation maps from multimodal patient data, significantly improving tumor extent identification and treatment planning. This specific application of AI for precise 3D mapping in prostate cancer represents a distinct innovative step in diagnostic and pre-procedural planning.

Support & Docs

Tie

Neither the provided structured facts nor web searches offered specific details on the depth or breadth of support and documentation for either product. Both companies are established in the healthcare AI space, suggesting a baseline level of support, but without further information, a definitive winner cannot be determined.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Avenda Health AI Prostate Cancer Planning Software CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)
Name Avenda Health AI Prostate Cancer Planning Software CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)
Company Avenda Health ConcertAI (an ASCO initiative)
Description FDA-cleared, AI-based decision support software that creates 3D cancer maps from patient data to precisely visualize prostate cancer extent, aiding physicians in treatment planning and decision-making for personalized care. A precision oncology platform by ConcertAI that uses AI and real-world data to identify patients for new therapies and clinical trials, streamlining oncology workflows.
Key Features AI-based decision support for prostate cancer planning; Generates 3D Cancer Estimation Maps (CEM) from MRI, biopsy, pathology, and PSA data; Precisely maps prostate cancer location and extent in 3D; Aids in surgical planning and treatment decision-making (active surveillance, prostatectomy, radiation, focal therapy); Improves identification of tumor extent (71% improvement, over 98% sensitivity in studies); Supports segmentation of MR image features and lesion documentation; Data exportable to compatible interventional or biopsy systems; Predicts extracapsular extension (ECE) risk. RxLinQ for identifying patients eligible for newly approved therapies; TriaLinQ for patient-to-trial matching; AI-driven insights from real-world data; Integration of clinical and genomic data; Streamlined clinical workflows; Support for research, treatment, and delivery decisions; Enterprise imaging integration (TeraRecon); Real-world evidence generation.
Specialties Oncology, Radiology, Urology Hematology, Oncology, Pathology

Videos

Demos, reviews, and walkthroughs featuring Avenda Health AI Prostate Cancer Planning Software and CancerLinQ SmartLinQ (RxLinQ & TriaLinQ).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Avenda Health's Unfold AI is a cloud-based platform that exports planning data in DICOM and other formats to integrate with clinical systems, assisting with segmentation, lesion evaluation, quantification, documentation, and pre-planning for diagnostic or interventional prostate procedures. CancerLinQ SmartLinQ aggregates and harmonizes clinical data from multiple EHR systems to provide a comprehensive patient overview and offers tools for quality management, clinical decision support, and patient-trial matching.
Avenda Health's Unfold AI has demonstrated improved identification of tumor extent (71% improvement, over 98% sensitivity in studies) and improved physicians' ability to identify cancer extent by 45x. It also accurately predicted extracapsular extension (ECE) risk, outperforming conventional methodologies like MRI and Partin Tables. CancerLinQ SmartLinQ uses AI and real-world data to identify patients for new therapies and clinical trials, aiming to improve personalized treatment decisions and patient outcomes by leveraging a vast dataset of nearly 7 million patient records.
Avenda Health's Unfold AI is specifically designed for prostate cancer care, aiding urologists, oncologists, and radiologists in treatment planning across the full prostate cancer care continuum, including active surveillance, focal therapy, surgery, and radiotherapy. CancerLinQ SmartLinQ is a broader precision oncology platform suitable for hematology, oncology, and pathology, focusing on identifying patients for new therapies and clinical trials across various cancer types.
While specific learning curve details are not provided, Avenda Health's Unfold AI is designed as a decision support software to assist physicians in making treatment decisions, suggesting an augmentative role rather than a complete overhaul of existing knowledge. CancerLinQ SmartLinQ aims to streamline oncology workflows and simplify patient-to-trial matching, which could imply a focus on user-friendly interfaces to reduce administrative burden.
Avenda Health is dedicated to bringing its technology to all practices and physicians treating prostate cancer patients, aiming to improve outcomes and preserve quality of life. CancerLinQ, an initiative of ConcertAI and originally founded by ASCO, emphasizes a 'learning network' approach and a long-term cooperation agreement with ASCO to continue providing quality solutions and SaaS technologies for the oncology community.
Avenda Health's Unfold AI is SOC2 Compliant, indicating adherence to rigorous security and privacy standards for cloud-based services. CancerLinQ securely compiles, harmonizes, analyzes, and de-identifies vast amounts of patient information to improve patient care and accelerate discovery, and provides aggregated de-identified data to subscribing practices and researchers.
Avenda Health's Unfold AI supports documentation of lesion evaluation and quantification, and pre-planning for diagnostic or interventional prostate procedures, which would inherently involve tracking the use of the software's outputs in clinical decision-making. CancerLinQ SmartLinQ provides insights and recommendations to assist oncologists in making informed treatment decisions and offers tools for monitoring and improving care quality through real-time data analysis and reporting, suggesting features that could support audit trails for decision support utilization.

More Comparisons

eCARTv5 Clinical Deterioration Suite (“eCART”) vs Google Med-PaLM 2
ChatGPT vs Google Med-PaLM 2
When choosing between ChatGPT and Google Med-PaLM 2, physicians should consider their primary use case and desired level of medical…
Brainomix 360 e-CTA vs Google Med-PaLM 2
DeepXray vs Google Med-PaLM 2

More matchups featuring Avenda Health AI Prostate Cancer Planning Software or CancerLinQ SmartLinQ (RxLinQ & TriaLinQ)

Backers

Who funded each tool's parent company.

Avenda Health AI Prostate Cancer Planning Software

AI Tool Finder
AI-powered search. Results may not be comprehensive.